Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent live attenuated seasonal influenza vaccine
- Development stage
- Unknown
- Lead developer
- MedImmune
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Trivalent live attenuated seasonal influenza vaccine (LAIV3) is a type of influenza vaccine formulated to protect against three strains of the influenza virus—two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage (B/Victoria). The "live attenuated" designation means the viruses in the vaccine are alive but weakened so they do not cause illness in healthy individuals. This formulation is typically administered as a nasal spray rather than an injection. The mechanism of action involves stimulating an immune response by mimicking natural infection in the upper respiratory tract, leading to immunity against circulating strains included in the vaccine. Live attenuated vaccines are generally recommended for healthy individuals aged 2–49 years without chronic medical conditions[6][7]. For the 2024–2025 U.S. season, all flu vaccines will be trivalent due to removal of B/Yamagata lineage from formulations[1][2][4].
- Other names
- LAIV3LAIV-3LAIV 3trivalent LAIVtrivalent nasal spray flu vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on trivalent live attenuated seasonal influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent live attenuated seasonal influenza vaccine.